Skip to main content

Table 1 Body and kidney weights, index of renal hypertrophy, and the renal function-related parameters in experimental animals at the end of the eight-week treatment

From: Ruscogenin ameliorates diabetic nephropathy by its anti-inflammatory and anti-fibrotic effects in streptozotocin-induced diabetic rat

 

Normal rats

 

STZ-diabetic rats

 

Vehicle

Vehicle

Ruscogenin (mg/kg/day)

Rosiglitazone (5 mg/kg/day)

0.3

1.0

3.0

Body weight (BW) (g/rat)

374.88 ± 17.92d

214.84 ± 14.95b

237.3 ± 17.21b

261.98 ± 18.32b,c

291.64 ± 16.24b,c

315.18 ± 18.10a,d

Plasma glucose (mg/dl)

92.78 ± 7.32d

423.12 ± 16.22b

418.27 ± 15.34b

412.37 ± 17.41b

409.87 ± 14.68b

262.31 ± 13.71b,c

HbAlc (%)

4.79 ± 1.03d

14.32 ± 1.79b

14.10 ± 1.63b

13.92 ± 1.84b

13.85 ± 1.65b

9.63 ± 1.59b,c

Kidney weight (KW) (g/rat)

1.38 ± 0.17d

2.28 ± 0.15b

2.07 ± 0.13b

1.93 ± 0.21b

1.85 ± 0.19a,c

1.79 ± 0.18a,d

KW/BW ratio (%)

0.37 ± 0.07d

1.06 ± 0.08b

0.87 ± 0.09b

0.74 ± 0.06b,c

0.62 ± 0.04a,d

0.57 ± 0.05a,d

24-h urine volume (ml/day)

8.96 ± 1.76d

27.30 ± 2.95b

21.84 ± 3.11b

19.65 ± 2.43b,c

17.65 ± 3.05a,c

15.34 ± 2.62a,c

24-h urine protein (mg/day)

6.60 ± 2.57d

28.36 ± 3.95b

24.11 ± 3.25b

19.85 ± 2.57,c

14.82 ± 3.29 a,d

10.26 ± 4.12a,d

Scr (μmol/l)

34.07 ± 5.26d

87.23 ± 7.96b

70.33 ± 5.83b,c

69.78 ± 4.92b,c

62.21 ± 5.61b,c

56.49 ± 6.92b,c

BUN (mmol/l)

6.51 ± 0.82d

18.85 ± 1.13b

15.68 ± 1.25b,c

14.27 ± 1.38b,c

12.66 ± 0.94b,c

9.71 ± 1.02a,c

Ccr (ml/min)

4.83 ± 0.63d

1.78 ± 0.71b

2.14 ± 0.56b

2.92 ± 0.61b

3.43 ± 0.59a,c

3.71 ± 0.74d

  1. STZ-diabetic rats were dosed by oral gavage once per day for eight weeks with ruscogenin at the indicated dosage, or rosiglitazone. Normal or STZ-diabetic rats receiving vehicle treatment were given the same volume of vehicle (distilled water) used to prepare test medications. Values (mean ± SD) were obtained for each group of 8 animals. aP < 0.05 and bP < 0.01 compared to the values of vehicle-treated normal rats, respectively. cP < 0.05 and dP < 0.01 compared to the values of vehicle-treated STZ-diabetic rats, respectively.